The Discovery of RGH-706, a Highly Efficacious MCH1 Receptor Antagonist, for the Treatment of Obesity and Insatiable Hunger
Clinical Snapshot
PICO Framework
| P — Population | DIO (diet-induced obesity) mice, Phase I healthy volunteers, Phase II Prader-Willi Syndrome patients |
| I — Intervention | RGH-706 (compound 37), a novel MCH1 receptor antagonist |
| C — Comparator | Not clearly specified in abstract - likely placebo or vehicle control |
| O — Outcomes | Body weight loss, receptor occupancy, safety profile, pharmacokinetics |
Bottom Line
RGH-706 represents a promising novel approach to obesity treatment through MCH1 receptor antagonism. The compound demonstrated statistically significant weight loss in preclinical models and has successfully completed Phase I clinical trials, indicating acceptable safety. However, clinical efficacy in humans remains to be definitively established. The mechanism targeting insatiable hunger may be particularly relevant for specific populations like Prader-Willi Syndrome patients. While encouraging, clinicians should await Phase III efficacy data before considering this as a treatment option. The drug discovery methodology appears robust, but the early-stage clinical development limits immediate clinical applicability. Further research is needed to establish optimal dosing, long-term safety, and comparative effectiveness against existing obesity treatments.
Key Findings
P Value: Statistically significant (exact value not provided)
Effect Size: Not quantified in abstract
Primary Outcome: Statistically significant body weight loss in DIO mice after 14 days
Nnt Or Sensitivity: High MCH1 receptor potency and excellent receptor occupancy profile
Confidence Interval: Not provided
Clinical Application
Early clinical phases completed successfully, suggesting feasible development pathway Would require TGA approval for clinical use; potential PBS listing consideration for obesity management if Phase III trials successful; aligns with RACGP obesity management guidelines emphasising multimodal approaches Patients with obesity, particularly those with insatiable hunger; potential application in Prader-Willi Syndrome
Abstract
The discovery and characterization of a novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole derivative MCH1 receptor antagonist (37) is disclosed. Starting from our previously investigated pyrazino[1,2-a]indole series and utilizing a scaffold hopping strategy, pyrimidine- and 1,4-diazepine-fused indole derivatives were designed and synthesized. Among these, only the prototype molecule containing the 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole scaffold emerged as a chemically stable and potent MCHR1 antagonist. Previous SAR knowledge coupled with an ex vivo occupancy assay helped us to optimize this advanced lead to our candidate (37). The high MCHR1 potency and excellent receptor occupancy profile of 37 translated into statistically significant body weight loss after 14 days in a DIO mice study, supporting the potential use of this compound as a weight loss agent. Compound 37 (RGH-706) has successfully completed a phase I (SAD & MAD) clinical study in the indication of obesity, followed by an exploratory Phase II study in patients with Prader-Willi Syndrome (PWS).
References
- 1.Beke, G., Boros, A., Keserű, G. M., Krámos, B., Szalai, K. K., Gere, A., Vastag, M., Thán, M., Varga, B., Balázs, O., Farkas, S., Lendvai, B., Greiner, I., & Éles, J. (2026). The Discovery of RGH-706, a Highly Efficacious MCH1 Receptor Antagonist, for the Treatment of Obesity and Insatiable Hunger. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02708
Related Research
European journal of radiology
A CT-based deep learning model to differentiate between benign and malignant adrenal lesions
3 Aug 2026
Journal of chemical information and modeling
A Unified Molecular Graph and Protein Language Model Framework for Predicting Human Drug-Hormone Receptor Interactions with Structure-Aware Validation
28 July 2026
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Differential effects of hormone therapy formulations on Parkinson's disease risk: a systematic review and meta-analysis
23 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service